39 results about "Methotrexate" patented technology

The invention belongs to the technical field of biological detection, and particularly relates to a method for synchronously and quantitatively detecting various folic acid metabolism related substances in trace plasma or serum, which comprises the following steps of: detecting a pretreated trace plasma or serum sample by adopting a liquid chromatography-tandem mass spectrometry method; the following nine folic acid metabolism related substances are synchronously and quantitatively detected: 5-formyl tetrahydrofolic acid, folic acid, 5-methyl tetrahydrofolic acid, S-adenosine-L-methionine, S-adenosine-L-homocysteine, vitamin B12, pyridoxamine, pyridoxine and pyridoxal. The invention further relates to application of the detection method in related detection of child neurodevelopment. According to the detection method, only trace plasma or serum is used, methotrexate is used for replacing an expensive isotope internal standard for more economical detection, and nine folate metabolism related substances can be accurately quantified at the same time. Therefore, the detection method disclosed by the invention has important clinical significance and wide market application prospect.

The invention relates to the technical field of medical nano-materials, and discloses a pH-responsive drug self-delivery nano-system and a preparation method and application thereof.The preparation method comprises the steps that 1, CMNPs is prepared, specifically, through an amidation reaction, the CMNPs are prepared from methotrexate and cis-aconitic anhydride; step 2, synthesizing DSPE-PEG-T12: synthesizing the DSPE-PEG-T12 by virtue of a nucleophilic addition reaction; step 3, preparing a T12 peptide modified erythrocyte membrane; and step 4, preparing T12-RBCM (at) CMNPs: modifying the T12 peptide of the targeted tumor cell transferrin receptor on an erythrocyte membrane, and coating the CMNPs to construct the nano-acquisition system T12-RBCM (at) CMNPs. According to the nano system T12-RBCM (at) CMNPs obtained by the scheme, the tumor cell uptake efficiency can be remarkably improved, cell apoptosis is induced, and proliferation is inhibited; the long-acting circulation and tumor targeting capability is realized, the tumor growth can be effectively inhibited, and the biological safety is good.

The application discloses a use of total iridoid glycosides in radix morindae officinalis in preparation of a medicine for reducing side effects of methotrexate, and the total iridoid glycosides in radix morindae officinalis are effective traditional Chinese medicine components prepared by extraction and separation from radix morindae officinalis medicinal materials. The total iridoid glycosides in radix morindae officinalis and main component crystal larkspur glycoside are combined with methotrexate to treat rheumatoid arthritis rats, and the animal experiment proves that the combined administration can effectively treat inflammation of the rheumatoid arthritis rats, and can inhibit bone loss, especially can effectively reduce side effects caused by methotrexate, reduce damage caused by methotrexate to the organism, make the application more safe and effective, and provide a new treatment strategy for rheumatoid arthritis.

The present invention discloses methods to prevent gout flares using IL-1β inhibitors. A method of treating gout patients using methotrexate, canakinumab, and pegloticase is described.

The present invention relates generally to genomics. In particular, the specification teaches a method of predicting subjects at risk of rheumatoid arthritis and the responsiveness of a subject towards methotrexate (MTX) treatment.

The present invention provides a fully human antibody that specifically binds to human FLT3 within extracellular domains 4 or 5 with high affinity. In particular disclosed is an antibody that specifically binds human FLT3 (SEQ ID NO. 43), comprising a CDRH1 having the sequence SYYMH (SEQ ID NO:2), a CDRH2 having the sequence IINPSGGSTSYAQKFQG (SEQ ID NO:3), a CDRH3 having the sequence GVGAHDAFDI (SEQ ID NO:4) or VVAAAVADY (SEQ ID NO:5), a CDRL1 having the sequence RSSQSLLHSNGNNYLD (SEQ ID NO:6) or RSSQSLLHSNGYNYLD (SEQ ID NO:7), a CDRL2 having the sequence LGSNRAS (SEQ ID NO:8), and a CDRL3 having the sequence MQGTHPAIS (SEQ ID NO:9) or MQSLQTPFT (SEQ II) NO: 11). The invention further provides a pharmaceutical composition for treating leukemia by administering an effective amount of an antibody either alone or in combination with an anti-cancer agent or treatment including methotrexate.

The invention provides a traditional Chinese medicine composition with an anti-inflammatory effect and a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following functional components: oldenlandia diffusa, rhizoma smilacis glabrae, astragalus membranaceus, radix aconiti carmichaeli, sargentgloryvine stem, madder, centipede and liquorice. The traditional Chinese medicine composition is prepared from the following components in parts by weight: 30-45 parts of oldenlandia diffusa, 30-45 parts of rhizoma smilacis glabrae, 30-45 parts of astragalus membranaceus, 10-15 parts of radix aconiti carmichaeli, 10-20 parts of sargentgloryvine stem, 10-15 parts of madder, 2-4 parts of centipede and 6-9 parts of liquorice through mixing and water extraction, and the components have a synergistic effect, so that the traditional Chinese medicine composition has the effects of detoxifying, expelling toxins and diminishing swelling, has a remarkable effect of treating rheumatoid arthritis and is free of toxic and side effects. The methotrexate pharmaceutical composition has the advantages that the methotrexate pharmaceutical composition has an obvious curative effect on treating joint swelling of a patient, especially has an obvious curative effect on improving joint swelling of a patient, can better reduce inflammation indexes ESR and CRP, has more advantages in long-term curative effects on improving joint pressing pain and joint swelling, and can effectively improve the drug effect of methotrexate and reduce toxic / side effects of methotrexate.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

This application discloses a method to solubilize poorly soluble drugs in a liquid crystal vehicle for long-acting injectables. Poorly soluble acidic drugs-hydrophobic basic compounds ion pairs are incorporated into liquid crystal vehicles to solubilize and slowly release the drug after parenteral administration. Ion pairs such as Meloxicam-Dodecylamine, Sulfadiazine-Dodecylamine, Methotrexate-Dodecylamine, Levothyroxine-Dodecylamine, Meloxicam-Tridodecylamine, and Meloxicam-Bupivacaine are incorporated into liquid crystal vehicles to solubilize and control release the drugs.

The invention discloses a composition for treating rheumatoid arthritis and application thereof, and belongs to the technical field of medicines. The technical problem to be solved is to provide the composition for treating rheumatoid arthritis, and the composition has a better effect of treating rheumatoid arthritis and is low in cost. The key point of the technical scheme is as follows: the composition for treating rheumatoid arthritis consists of cannabidiol and methotrexate.

This invention relates to the technical field of nanomedicine synthesis and discloses a method for synthesizing nanomedicines for the treatment of rheumatoid arthritis, comprising the following steps: S10: obtaining or preparing high-purity, small-particle-size CaO2 nanoparticles; S20: encapsulating the CaO2 nanoparticles in a ZIF67 system to obtain CaO2@ZIF67; S30: dissolving methotrexate in methanol to obtain an MTX additive solution; dissolving CaO2@ZIF67 in methanol, then adding the MTX additive solution dropwise, and stirring thoroughly; finally, purifying, washing, and drying the obtained product to obtain CaO2@MTX@ZIF67. Targeting the two main pathological features of rheumatoid arthritis, namely inflammation and hypoxic microenvironment, this invention uses ZIF67-loaded calcium peroxide combined with methotrexate to treat the inflammatory sites of rheumatoid arthritis. The constructed product can inhibit the expression of tumor necrosis factor-α / interleukin-6, overcome the hypoxic nature of rheumatoid arthritis, and achieve the technical characteristics of alleviating inflammatory symptoms and altering disease progression, low cost, few side effects, and long-term treatment.

Provided herein are compositions comprising disodium levofolinate. Also provided are processes for preparing compositions comprising disodium levofolinate. Also provided are compositions comprising disodium levofolinate prepared by the processes provided herein.Also provided are methods of treating folic acid deficiency in a subject in need thereof, comprising administering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering 5-fluorouracil and a composition provided herein to the subject. Also provided are methods of reducing the immediate toxic effects of methotrexate overdose in a subject in need thereof, comprisingadministering a composition provided herein to the subject. Also provided are methods of treating cancer in a subject in need thereof, comprising administering high-dose methotrexate and a composition provided herein to the subject. Also provided are methods of treating megaloblastic anemia in a subject in need thereof, comprising administering a composition provided herein to the subject.

The invention discloses a prescription identification matching method for methotrexate administration, particularly relates to the field of intelligent prescriptions and medical informatics, and is used for solving the problem that in the prior art, a methotrexate administration scheme mainly depends on doctor experience adjustment and is difficult to carry out individualized matching by comprehensively utilizing historical case data. A disease activity manifold trajectory is constructed by extracting historical clinical records in electronic medical records of a target patient, a delay accumulation rule of disease state change after administration is analyzed in combination with prescription records to obtain drug effect attenuation state parameters, patient attenuation subtypes are identified on the basis, and causal relationship analysis is performed to obtain a causal contribution weight vector; and searching similar patient groups from a historical case library, generating a candidate intervention track set containing success probability distribution, and finally generating a methotrexate administration scheme recommendation list according to success probability sorting, thereby providing a more reasonable methotrexate administration scheme with reference value for a target patient.

The disclosure provides methods of treating gout in patients comprising administering a PEGylated uricase. Also provided are methods of treating gout in patients comprising co-administering a PEGylated uricase and methotrexate (MTX). Also provided are methods of reducing immunogenicity of a PEGylated uricase and prolonging the urate lowering effect comprising co-administration of the PEGylated uricase and MTX.

This disclosure provides double-stranded nucleic acid compositions incorporating uracil, gemcitabine, and methotrexate (MTX). More specifically, this disclosure reveals that modification of double-stranded microRNA nucleotide sequences with 5-fluorouracil, gemcitabine, and methotrexate (MTX) enhances the therapeutic efficacy and tumor specificity of tumor suppression. Accordingly, this disclosure provides various nucleic acid (e.g., microRNA) compositions incorporating 5-fluorouracil, gemcitabine, and methotrexate (MTX) into their nucleic acid sequences, as well as methods for using them. This disclosure further provides pharmaceutical compositions (e.g., formulations) containing the modified nucleic acid compositions, and methods for treating cancers such as pancreatic cancer. This is a platform technology that can be applied to other tumor suppressor miRNAs and siRNAs.

The present invention relates to a method of treating a patient with moderate to severe active rheumatoid arthritis and inadequate response to Methotrexate by administering to the patient a therapeutically effective amount of compound of Formula 001: or a stereoisomer, racemate, tautomer, isotopologue, prodrug, or pharmaceutically acceptable salt thereof.

Methotrexate-containing polymersomes and methods for treating ectopic pregnancy or for treating gestational choriocarcinoma using the methotrexate-containing polymersomes.

The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.

This invention discloses a halogen-free organic solderable protective agent and its preparation method, comprising the following components at the following mass concentrations: 2-phenylimidazolium 2.5-5 g / L, 2-benzylbenzimidazole 0.5-1.0 g / L, pyromellitic anhydride 30-60 mg / L, diethylene glycol 1-2 ml / L, ethanol 5-10 ml / L, p-nitrobenzoic acid 10-30 mg / L, and methotrexate 10-30 mg / L; the temperature is 35-45℃; the pH is controlled within the range of 3.8-4.2; and the balance is deionized water. This invention can be widely applied to the surface treatment process of electronic products, achieving a thickness rate of over 0.35 μm in 1 minute. The resulting film is uniform, transparent, and glossy, with strong solderability. It exhibits good resistance to sulfuric acid concentrations below 0.1 mol / L and readily dissociates in 5% hydrochloric acid and 5 ml / L acetone solutions, simplifying rework.

A method for treating moderate to severe active rheumatoid arthritis in a patient, which method comprises administering, to the patient, a therapeutically effective amount of a compound as shown in 001, a stereoisomer, racemate, tautomer, isotopic marker, prodrug thereof or a pharmaceutically acceptable salt thereof; and the patient responds poorly to methotrexate. The compound as shown in formula 001 has the below structure.

Disclosed herein are antibodies that specifically bind to a methotrexate analyte. Such antibodies can be used to detect a methotrexate analyte in a sample, such as in a homogeneous enzyme immunoassay method. Hapten structures to elicit such antibodies are also described. Conjugates useful in immunoassays that use such antibodies are also described.

The invention discloses a nano-carrier for precise sequential controlled release of a synergistic drug and a preparation method. The preparation method comprises the following steps: preparing a prussian blue nano-cage loaded with 5-fluorouracil; the outer layer of the Prussian blue nanocage is coated with the methotrexate functionally modified hyaluronic acid; and constructing a co-delivery carrier 5-FU (at) PB Cage / MTX loaded with a synergistic drug. The carrier triggers MTX release in a tumor site slightly acidic environment; after a required time interval, near-infrared light is applied to the enriched part of the carrier, the local temperature is increased by means of the photothermal conversion effect of PB Cage, the phase change material is promoted to melt and flow out, and then controllable release of 5-FU is achieved. The problems that a traditional co-delivery carrier is disordered in time sequence and poor in synergistic effect are solved, a brand new carrier design thought is provided for precise tumor chemotherapy, and important theoretical and application values are achieved for promoting conversion of nano-drugs from basic research to clinic, improving tumor treatment efficiency and reducing toxic and side effects.

The invention relates to an application of an aromatic acylhydrazone compound or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating rheumatoid arthritis, and an application of the aromatic acylhydrazone compound and methotrexate in preparation of the medicine for treating rheumatoid arthritis. When the aromatic acylhydrazone compound is injected into an articular cavity, the arthritis index score of AA rats can be remarkably reduced, joint symptoms are effectively improved, synovial hyperplasia and cartilage injury are relieved, and TNF-alpha induced RA-FLSs abnormal activation can be remarkably inhibited. Meanwhile, the aromatic acylhydrazone compound disclosed by the invention is combined with methotrexate for use, so that the aromatic acylhydrazone compound has a better effect of treating rheumatoid arthritis and has relatively high clinical application value and development prospect.

The present application relates to the technical field of nanomedicine preparation, and particularly relates to a nanocarrier drug delivery system, a preparation method and application thereof. The nanocarrier drug delivery system comprises: extracellular vesicles loaded with methotrexate, lipid nanoparticles loaded with HIF-1 alpha shRNA plasmid, an outer carrier material and azobenzene; and the outer carrier material is modified with cell-penetrating peptide TAT-AT7. The transmembrane hypoxia-responsive hyaluronic acid nanocarrier drug delivery system prepared by the present application has good penetration and safety, is suitable for eye drop administration for treating ocular vascular proliferative diseases, has precise response drug release capacity for the hypoxic site of the lesion, target capacity for vascular endothelial cells and double treatment effects of synergistic anti-inflammatory and anti-angiogenic, and has a wide application prospect.

The present disclosure provides methods of reducing blood phenylalanine concentration using a prokaryotic phenylalanine ammonia-lyase (PAL) in combination with methotrexate (MTX).

The invention relates to the technical field of traditional Chinese medicines, in particular to a flos genkwa strip extract with rheumatoid arthritis resistance as well as a preparation method and application of the flos genkwa strip extract. The preparation method comprises the following steps: heating and extracting a daphne genkwa strip raw material by adopting an ethanol water solution, concentrating an obtained extracting solution, and extracting by using n-butyl alcohol to obtain an extract; and purifying the extract by macroporous adsorption resin column chromatography, carrying out gradient elution by adopting an ethanol-water solution with increasing concentration, collecting a high-concentration ethanol elution component, and concentrating to obtain the target extract. Pharmacodynamic evaluation performed by a collagen-induced arthritis rat model shows that the flos genkwa strip extract can remarkably improve symptoms such as arthrocele, and the treatment effect of a high-dose group is superior to that of Chinese patent medicine collateral pain eliminating tablets recorded in Chinese pharmacopoeia (2020 edition) and is equivalent to that of positive control medicine methotrexate. The preparation method disclosed by the invention is efficient and stable, and the obtained product is clear in activity and has a wide prospect of being developed into an innovative traditional Chinese medicine for resisting rheumatoid arthritis.

This invention relates to the field of pharmaceutical preparation technology, specifically to a sulfachlorpyridazine sodium-methotrexate suspension, its preparation method, and its application. The sulfachlorpyridazine sodium-methotrexate suspension of this invention comprises the following components per 100 ml: 20-50 g of sulfachlorpyridazine sodium, 4-10 g of methotrexate, 0.1-0.25 g of suspending agent, 0.05-0.125 g of wetting agent, 0.2-0.5 g of antioxidant, 0.1-0.25 g of disodium edetate, and purified water to a final volume of 100 ml. The suspension prepared by this invention can delay the in vivo clearance of sulfachlorpyridazine sodium, prolong the synergistic effect time, and improve its bioavailability; in the treatment of coccidiosis infection in chickens and sheep, it can significantly improve weight gain, reduce intestinal lesion values, rapidly clear oocysts, and maintain a long-lasting protective effect after drug withdrawal.